Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy

Tullett, Kirsteen M., Lahoud, Mireille H. and Radford, Kristen J. (2014) Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy. Frontiers in Immunology, 5 MAY: 1-1. doi:10.3389/fimmu.2014.00239

Author Tullett, Kirsteen M.
Lahoud, Mireille H.
Radford, Kristen J.
Title Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy
Formatted title
Harnessing human cross-presenting CLEC9A+XCR1+ dendritic cells for immunotherapy
Journal name Frontiers in Immunology   Check publisher's open access policy
ISSN 1664-3224
Publication date 2014-05-22
Year available 2014
Sub-type Article (original research)
DOI 10.3389/fimmu.2014.00239
Open Access Status DOI
Volume 5
Issue MAY
Start page 1
End page 1
Total pages 4
Place of publication Lausanne, Switzerland
Publisher Frontiers Research Foundation
Collection year 2015
Language eng
Formatted abstract
Dendritic cells (DC) are professional antigen presenting cells (APCs) that play a pivotal role in the induction and regulation of immune responses, including the induction of cytotoxic T lymphocyte (CTL) responses. They are an important focus for the development of vaccines against cancers and many pathogens, including HIV and malaria, where CTL responses are required for protection and disease eradication. DC loaded ex vivo with tumor antigen (Ag) have been administered as vaccines to cancer patients for over 15 years. They are well-tolerated and induce immune responses, including some clinical regressions, but there is clearly room for improvement (1). The DC network in both mice and humans is heterogeneous, with specialized DC subsets driving specific immune functions (2). New developments in our understanding of DC biology have identified a subset of DC characterized by the expression of novel markers CLEC9A (DNGR-1) (3, 4) and XCR1 (5, 6) as being important for the induction of CTL responses (7). Vaccine strategies that deliver Ag and activators directly to CLEC9A+XCR1+ DC in vivo promise to overcome many of the logistical issues associated with in vitro-derived vaccines, allowing precision and specificity of the desired immune response (8). Here, we discuss the biological properties of CLEC9A+XCR1+ DC that make them such attractive targets for CTL vaccines and new vaccine approaches to target them in vivo.
Keyword Dendritic cells
DC targeting
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 7 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 19 Aug 2014, 02:20:50 EST by System User on behalf of School of Biomedical Sciences